Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar’s proprietary and proven chemistry platform in the discovery and design of our new drug candidates.
Our success is rooted in four key elements:
- Our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners
- Our unique research and development pipeline of new investigational medicines in cancer and immunology
- Our proprietary and proven science and technology approach that fuels our discovery efforts
- Our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases
OncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. OncoSec’s lead product candidate, TAVO™, enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. TAVO has demonstrated promising anti-tumor activity in melanoma and four other cancer types both as a monotherapy and in combination with anti-PD-1 checkpoint inhibitors. TAVO is currently being evaluated in combination with KEYTRUDA® (pembrolizumab) in two ongoing KEYNOTE clinical trials – a pivotal study in anti-PD-1 checkpoint resistant metastatic melanoma and a phase 2 study in metastatic triple negative breast cancer. In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator, to target deep internal tumors, such as liver, lung or pancreatic cancers.
For more information, please visit www.oncosec.com.
This summit is specifically focused on the next generation of immunocytokines in development for cancer therapy – Allowing you to meet with the most relevant and senior leaders in the industry.
Mechanisms of action, adverse clinical effects, controlling and sustaining cytokine release are just some of the topics that will be dissected through interactive panel discussions and open Q&A.
Hear from the key players currently paving the way for cytokine therapeutic success. Both preclinical and clinical programs take center stage to present the varied interleukins in development to attack multiple cancers.
With numerous immunotherapies exploiting cytokines coming down the pipeline, the timing of the Next-Gen Cytokine Therapeutics Summit is ideal and warranted. This event provides the opportunity for those who have pioneered the space and also the newcomers in the industry to get together and learn more about this dynamic and exciting field.
Modulating cytokine signaling is proving to be a powerful strategy for treating complex and serious diseases. The major breakthroughs of the future will require innovative new strategies like protein design to address long-standing challenges.
The Next-Gen Cytokine Therapeutics Summit is a perfect event to bring together innovators and thought leaders in this rapidly-evolving field.It will undoubtedly be full of rich, generative, and thought-provoking discussions that will lay the groundwork for the cytokine therapeutics of tomorrow.
With several new and exciting cytokine programs in early-stage development, but many challenges ahead, The Next-Gen Cytokine Therapeutics Summit is certain to be an invaluable event for both experts in the field and newcomers alike.
Willem Overwijk, PhD received his MS in Medical Biology from Utrecht University in the Netherlands, trained at the Surgery Branch, National Cancer Institute in Bethesda, MD and received his PhD in Biochemistry and Molecular Biology from the George Washington University in Washington, DC. He completed his postgraduate training at the Netherlands Cancer Institute in Amsterdam before accepting a faculty position at MD Anderson Cancer Center where he focused on translational research in Immuno-Oncology. In 2018 he joined Nektar Therapeutics in San Francisco as vice president of oncology research to continue working on bringing novel agents in Immuno-Oncology to patients.
Dr. Chris Lawrence, PhD, Vice President of Development at Neumedicines Inc, is an accomplished immunologist and biochemist with over 20 years of R&D experience in the life sciences industry, covering multiple biological modalities and therapeutic areas. Chris previously held positions of increasing responsibility at Xencor, Sunesis, Amgen (formerly Tularik), and Sanofi, supporting discovery through to clinical development. Chris received his PhD, while researching at the Immunology Dept, Cambridge University, UK, and his BSc from Newcastle-Upon-Tyne University, UK.
Dr. Kimberly Schluns is an Associate Professor in the Department Immunology at MD Anderson Cancer Center. Through her research, she seeks to better understand the mechanisms that regulate antigen-specific CD8 T cell responses and their subsequentdifferentiation into long-lived, functional memory T cells. Her lab has published numerous findings on the role of cytokines, particularly Interleukin-15, in the generation and maintenance of memory CD8 T cells. IL-15 also enhances responses by cytotoxic cells and has potent anti-tumor properties. Currently, the lab is attempting to identify mechanisms that regulate IL-15 responses in the tumor microenvironment and by IL-15 agonists used in cancer immunotherapy. Ultimately, the insights Dr. Schluns gains by unraveling these mechanisms could be used to guide development of new cancer vaccines and tumor immunotherapies.
Matthew Bernett, Ph.D. is currently a Director in the Protein Engineering group at Xencor, Inc. He has been involved in all aspects of the company’s research efforts, leading to over ten programs currently in clinical development. Presently his work focuses on the design of novel and more druggable cytokine-based therapeutics, a class of drugs which has proven challenging.
Laurence joined Ziopharm Oncology as chief executive officer in 2015 after the Company licensed technology for a non-viral approach for genetically modifying T cells from MD Anderson Cancer and the University of Minnesota. This technology is designed to reduce the cost and complexity of genetically modified T cells. Prior to joining Ziopharm, Laurence was a tenured Professor at MD Anderson with joint appointments in the Division of Pediatrics and Department of Immunology. There, he served as Section Chief of Cell Therapy at the Children’s Cancer Hospital and helped lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. He remains a visiting scientist at MD Anderson. Laurence has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and he completed his training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.
Dr. Twitty brings over 20 years of experience in tumor immunology and cancer immunotherapy, including the discovery and development of OncoSec’s leading clinical immune monitoring and biomarker program.
Dr. Twitty earned his PhD from Oregon Health & Science University where his work was focused on novel tumor vaccine strategies and was awarded an American Cancer Society fellowship training grant for his post-doctoral studies in Dr. Bernard Fox’s Molecular Tumor Immunology Laboratory. After developing a pre-clinical and clinical immunological program focused on glioblastoma at Tocagen, Dr. Twitty joined Oncosec. Previously, Dr. Twitty held scientific positions of increasing responsibility at Bayer Pharmaceuticals and Cell Genesys, Inc.
Heather Losey was trained in protein biochemistry, structure and function, with a Ph.D. from Harvard Medical School and a postdoc in the Harvard Chemistry Department. Heather joined Wyeth in 2006 in metabolic diseases and hemophilia research before moving to Alkermes to support the expansion of biologics and oncology research. There, Heather led the protein engineering efforts, including ALKS 4230, for which she has been program lead from inception into ongoing clinical studies.
Dr. Sauer’s career goal is to deliver transformative therapeutics for major diseases through scientific excellence, team work in high performing environments, and strong interactions with the academic community.
He is an internationally recognized expert in the areas of immuno-oncology, lymphocyte signaling and development, hematopoietic stem cell biology, cancer and mechanisms of drug resistance. Dr. Sauer has authored over 47 research articles, many in leading scientific journals. He serves as a reviewer for major scientific journals and grant review panels, and organizes as well as presents his research at major scientific meetings and conferences. Dr. Sauer is a previous trustee of the San Diego/Hawaii chapter of The Leukemia and Lymphoma Society, and a member of the American Association of Immunologists, the American Association for Cancer Research, and the American Association of Hematology. His important scientific contributions were recognized through career development awards from The Leukemia and Lymphoma Society, and from the American Association of Immunologists.
Dr. Sauer received his Ph.D. in biochemistry in 1996 from the University of Tübingen in Germany. After postdoctoral work at the Merck Research Laboratories in Rahway, NJ, he spent five years as a group leader and principal investigator at the Genomics Institute of the Novartis Research Foundation in La Jolla, CA. From 2006 through 2015, Dr. Sauer was faculty at The Scripps Research Institute, where he still holds an adjunct appointment. 2015-2018, he built and led a cancer immunopharmacology group at Pfizer La Jolla. In 2018, he transitioned into his current role at Torque Therapeutics, where he develops innovative immunomodulator-enhanced Deep PrimedTM T cell immunotherapies for cancer.
Carl brings scientific, product, and business development experience spanning multiple industries. Prior to joining Neoleukin Therapeutics, he served as a Senior Fellow at the Institute for Protein Design, where he led projects focused on the application of computational protein design to address unmet needs in oncology and autoimmunity. In 2014, he co-founded Ansible Marketing, which develops machine learning tools to automate omni-channel communications for small and medium businesses. Over the past decade, Dr. Walkey has co-authored over a dozen research works and received numerous prestigious scholarships and awards, including the Alexander Graham Bell Canada Graduate Scholarship and NSERC Postdoctoral Fellowship. Dr. Walkey received his PhD from the University of Toronto, where he applied machine learning to develop enhanced nanomedicines for drug delivery and vaccine development.
Khaled Ali, Ph.D. has 10 years + experience in the field of cancer immunology, he obtained his PhD from University College London and completed post-doctoral studies at the Ludwig Institute for Cancer Research. Before joining Amgen, he was a senior fellow at the Barts Cancer Institute in London where his interests focused on understanding the role of Regulatory T cells in cancer. He is currently a Senior Scientist at Amgen, leading a group interested in understanding the molecular mechanisms that drive T cell dysfunction in cancer.
- Tuesday, November 3rd 2020
Understanding Mechanisms of Action
Chris Lawrence, VP, Development, Neumedicines
Willem Overwijk, VP of Oncology Research, Nektar Therapeutics
Adi Diab, Associate Professor, Lead Investigator of Bempegaldesleukin Clinical Program, MD Anderson Cancer Center
Next-Gen Cytokine Therapeutics
- Heather Losey, Director, Program Lead in Immuno-Oncology, Alkermes
- Carl Walkey, VP of Corporate Development, Neoleukin Therapeutics
- Matthew Bernett, Director, Xencor
- Laurence Cooper, CEO, Ziopharm
Kimberly Schluns, Associate Professor, MD Anderson Cancer Center
Chris Twitty, Chief Scientific Officer, OncoSec
- Chris Twitty, Chief Scientific Officer, OncoSec
- Chris Lawrence, VP of Development, Neumedicines
Cytokines in Combination Therapy
Carl Walkey, VP of Corporate Development, Neoleukin Therapeutics
Heather Losey, Director, Program Lead in Immuno-Oncology, Alkermes
Controlling and Sustaining Cytokine Release
Matthew Bernett, Director, Xencor
Laurence Cooper, CEO, Ziopharm
Karsten Sauer, VP of Immunology, Torque Therapeutics
- Kimberly Schluns, Associate Professor, MD Anderson Cancer Center
- Karsten Sauer, VP of Immunology, Torque Therapeutics
- Willem Overwijk, VP of Oncology Research, Nektar Therapeutics
- Khaled Ali, Senior Scientist, Amgen
Chris Lawrence, VP, Development, Neumedicines
Hosted by Nektar Therapeutics
We strive to provide inspirational venues that can provide the space needed for an open and widely networked event.
This year’s summit is being held at Boston University’s Metcalf Trustee Center.
This Center offers elegance with a view. With crystal chandeliers and an adjacent cocktail lounge with floor-to-ceiling windows overlooking Boston, this venue makes for the perfect place for learning, networking and relaxing.
Full details of the venue location, catering and travel will be included in your registration pack.
Our attendees tell us that one of the main reasons they attend our summits is to advance partnership discussions and forge new business relationships. To facilitate this (and help us to fund the event) we have a limited number of partnership opportunities. This means that our partners can be confident they can have the meaningful conversations they seek – and our attendees know that the composition of the audience is just right.
We invite you to get in touch for a no-obligation conversation. We will share our audience data with you and help you determine whether The Next-Gen Cytokine Therapeutics Summit is the right fit for you.
Register for the Event
For pricing and booking options please click the button to go to the registration page.